Eli Lilly's Oral Weight-Loss Drug Foundayo Shows Superior Data Over Novo Nordisk's Ozempic Tablet in Indirect Comparison
nashnova research
Eli Lilly says its oral drug Foundayo outperformed Novo Nordisk's Ozempic pill on weight loss and blood-sugar control in type 2 diabetes patients — but the data come from an indirect comparison, not a head-to-head trial, and Novo disputes the scope.
How much better did Foundayo perform?
Lilly says the Foundayo 17.2 mg group lost 1.5% to 2.4% more body weight and cut A1C (a marker of average blood sugar over three months) by an extra 0.3% to 0.6% versus oral semaglutide 25 mg.
This means → in the oral weight-loss race, Lilly now claims a quantifiable efficacy gap, not just parity.
The data come from two completed late-stage trials analyzed side by side — consistent across multiple statistical methods, but not a head-to-head study.
How reliable is an indirect comparison?
An indirect comparison — pooling results from two separate trials rather than testing both drugs in the same patients — is a standard industry method when head-to-head data do not yet exist.
Lilly SVP Rachel Batterham acknowledged that "head-to-head trials ultimately provide the best basis for comparing medicines," but argued the current method still offers informative data points.
In plain terms = this is a scrimmage, not the championship game — directionally useful, but it cannot settle the score.
Why does Novo Nordisk push back?
Novo told Reuters the comparison covers type 2 diabetes patients, not obesity patients.
This means → type 2 diabetes patients typically lose less weight in clinical trials than obesity patients, so claiming "superior weight loss" from this population narrows the scope considerably.
Added context: Novo's 25 mg oral semaglutide (the active ingredient in the Ozempic pill) is not yet approved in the U.S. for type 2 diabetes — the FDA decision is expected by late 2026.
What are the two giants really fighting over?
Lilly and Novo Nordisk are the two dominant players in the global weight-loss drug market. Both sell GLP-1 drugs — a class that works by regulating blood sugar and suppressing appetite.
Novo's Ozempic pill shares the same active ingredient, semaglutide, with its blockbuster Wegovy; Lilly's Foundayo is an oral tirzepatide.
This reflects a broader shift: the oral format is becoming the next competitive frontier — whoever leads on convenience, tolerability, and efficacy at the same time captures the growth market.
Can this data change anything?
The indirect comparison helps Lilly seize an early edge in the market narrative, but it cannot substitute for regulator-grade head-to-head evidence.
In plain terms = this is a trailer, not the feature film — the real market reshuffling waits for head-to-head trial results.
For investors, the short-term question is narrative control (whose data story is more convincing); the long-term question is when the definitive trial data land.
市场有风险，内容仅供研究参考，不构成投资建议。